Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1203d70402f3207a082156986a3c3159 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-522 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 |
filingDate |
1997-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6761f5a43d56552cbfd5be8ec998650c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59ed233b9548248d36565585efe05dd7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a07ce7c31eefd75407f89d3b361a202c |
publicationDate |
1998-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2265455-A1 |
titleOfInvention |
Granulocyte chemotactic protein 2 variant |
abstract |
The present invention provides a polynucleotide which identifies and encodes a novel human granulocyte chemotactic protein 2 variant (NGCP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding NGCP. The invention also provides for the production and use of substantially purified NGCP in pharmaceutical compositions to stop cell division in cancerous cells. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts encoding NGCP and anti-NGCP antibodies which specifically bind to NGCP. |
priorityDate |
1996-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |